Gene therapy for refractory epilepsy
Epilepsy affects 1% of the population and is poorly controlled by drugs in one third of affected people. Many patients with refractory epilepsy are not candidates for surgery because of proximity of the seizure focus to eloquent cortex. We have developed several strategies to treat experimental focal epilepsy in rodent models using gene therapy, based on expression of potassium channels, optogenetics and chemogenetics. Some of these are potentially amenable to clinical translation.